Strong US sales and Ratiopharm drug boost Israeli generic drugs maker Teva

first_img whatsapp Tuesday 2 November 2010 9:29 pm KCS-content whatsapp Read This NextRicky Schroder Calls Foo Fighters’ Dave Grohl ‘Ignorant Punk’ forThe WrapCNN’s Brian Stelter Draws Criticism for Asking Jen Psaki: ‘What Does theThe WrapDid Donald Trump Wear His Pants Backwards? Kriss Kross Memes Have AlreadyThe WrapHarvey Weinstein to Be Extradited to California to Face Sexual AssaultThe WrapNewsmax Rejected Matt Gaetz When Congressman ‘Reached Out’ for a JobThe WrapPink Floyd’s Roger Waters Denies Zuckerberg’s Request to Use Song in Ad:The Wrap’The View’: Meghan McCain Calls VP Kamala Harris a ‘Moron’ for BorderThe Wrap’Sex and the City’ Sequel Series at HBO Max Adds 4 More ReturningThe Wrap2 HFPA Members Resign Citing a Culture of ‘Corruption and Verbal Abuse’The Wrap Show Comments ▼ Strong US sales and Ratiopharm drug boost Israeli generic drugs maker Teva Share Teva Pharmaceutical Industries, the world’s biggest maker of generic drugs, posted higher quarterly net profit that beat expectations, boosted by strong US sales and its acquisition of Germany’s Ratiopharm.Third quarter sales in North America rose 22 per cent to $2.72bn while generic sales in the US jumped 34 per cent to $1.63bn, Israel-based Teva said yesterday.Teva attributed the increase to the exclusive launch of a generic version of Wyeth’s $2.75bn-a-year antidepressant Effexor XR in the quarter as well as strong sales of generic drugs launched in previous quarters.The results also reflected strong sales of Copaxone, Teva’s leading branded treatment for multiple sclerosis, it said.Quarterly earnings excluding one-time items rose 46 per cent to $1.30 a share while sales rose 20 per cent to $4.25bn. Exchange rates stripped out $122m in the quarter compared with a year ago though the effect on operating profit was negligible, Teva said.Analysts on average expected Teva to earn $1.27 a share on sales of $4.37bn. Tags: NULLlast_img read more

Bamburi Cement Limited ( HY2020 Interim Report

first_imgBamburi Cement Limited ( listed on the Nairobi Securities Exchange under the Building & Associated sector has released it’s 2020 interim results for the half year.For more information about Bamburi Cement Limited ( reports, abridged reports, interim earnings results and earnings presentations, visit the Bamburi Cement Limited ( company page on AfricanFinancials.Document: Bamburi Cement Limited (  2020 interim results for the half year.Company ProfileBamburi Cement Limited manufactures and sells cement and cement products for the building sector in Kenya and Uganda. The company exports its products to Reunion, Uganda and Mayotle. Brands in its retail range include Powermax, Powercrete, Nguvu, Supaset, Multipurpose, Powerplus and Roadcem. Pre-cast concrete paving blocks sell under the BamburiBlox name. The company also supplies precast molded cement products used for drainage, edge constraints, fencing and walling and ready-mix cement. Bamburi Cement Limited offers its service to rehabilitate quarries and owns and maintains a nature and environmental park developed from a rehabilitated quarry. The company was founded in 1951 and has its head office in Nairobi, Kenya. Bamburi Cement Limited is a subsidiary of Lafarge Holcim Limited (SA). Bamburi Cement Limited is listed on the Nairobi Securities Exchangelast_img read more